189 related articles for article (PubMed ID: 32816908)
1. Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer.
Schonhoft JD; Zhao JL; Jendrisak A; Carbone EA; Barnett ES; Hullings MA; Gill A; Sutton R; Lee J; Dago AE; Landers M; Bakhoum SF; Wang Y; Gonen M; Dittamore R; Scher HI
Cancer Res; 2020 Nov; 80(22):4892-4903. PubMed ID: 32816908
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.
Greene SB; Dago AE; Leitz LJ; Wang Y; Lee J; Werner SL; Gendreau S; Patel P; Jia S; Zhang L; Tucker EK; Malchiodi M; Graf RP; Dittamore R; Marrinucci D; Landers M
PLoS One; 2016; 11(11):e0165089. PubMed ID: 27851748
[TBL] [Abstract][Full Text] [Related]
3. Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer.
Barnett ES; Schultz N; Stopsack KH; Lam ET; Arfe A; Lee J; Zhao JL; Schonhoft JD; Carbone EA; Keegan NM; Wibmer A; Wang Y; Solit DB; Abida W; Wenstrup R; Scher HI
Eur Urol; 2023 Feb; 83(2):112-120. PubMed ID: 36123219
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
5. Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.
Graf RP; Hullings M; Barnett ES; Carbone E; Dittamore R; Scher HI
Eur Urol; 2020 Feb; 77(2):170-177. PubMed ID: 31648903
[TBL] [Abstract][Full Text] [Related]
6. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
[TBL] [Abstract][Full Text] [Related]
7. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
[No Abstract] [Full Text] [Related]
8. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
9. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
11. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.
Malihi PD; Graf RP; Rodriguez A; Ramesh N; Lee J; Sutton R; Jiles R; Ruiz Velasco C; Sei E; Kolatkar A; Logothetis C; Navin NE; Corn P; Aparicio AM; Dittamore R; Hicks J; Kuhn P; Zurita AJ
Clin Cancer Res; 2020 Aug; 26(15):4143-4153. PubMed ID: 32341031
[TBL] [Abstract][Full Text] [Related]
12. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
[TBL] [Abstract][Full Text] [Related]
14. Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Chai S; Matsumoto N; Storgard R; Peng CC; Aparicio A; Ormseth B; Rappard K; Cunningham K; Kolatkar A; Nevarez R; Tu KH; Hsu CJ; Malihi P; Corn P; Zurita A; Hicks J; Kuhn P; Ruiz-Velasco C
Mol Cancer Res; 2021 Dec; 19(12):2036-2045. PubMed ID: 34462330
[TBL] [Abstract][Full Text] [Related]
15. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
17. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
19. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
